LONDON – Pfizer Inc. is scrapping development of OAP-189, an obesity drug originally discovered by UK company Thiakis Ltd., and said it intends to divest the program, with implications for the future milestones due to Imperial Innovations Group plc, the former majority owner of Thiakis.